EATG » ViiV Healthcare presents data on long-acting, injectable two-drug regimen at CROI 2019

ViiV Healthcare presents data on long-acting, injectable two-drug regimen at CROI 2019

ViiV Healthcare presents positive, 48-week data from two pivotal phase III studies showing long-acting, injectable two-drug regimen of cabotegravir and rilpivirine has similar efficacy to daily, three-drug oral treatment in adults living with HIV-1 infection

— Comprehensive data from ATLAS and FLAIR studies presented at the 2019 Conference on Retroviruses and Opportunistic Infections show investigational long-acting injectable to be effective in maintaining viral suppression

Read the full press release here.


 

Source:
ViiV Healthcare
News categories: HIV treatment, CROI 2019